


Amendments To The Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound represented by formula (1):

Formula 1



wherein

R<sup>1</sup>, R<sup>2</sup> and R<sup>5</sup> are each independently selected from a hydrogen atom, a halogen atom, a C<sub>1</sub>-C<sub>6</sub> alkyl group which may be substituted with one or more halogen atoms and a C<sub>1</sub>-C<sub>6</sub> alkoxy group which may be substituted with one or more halogen atoms;

R<sup>3</sup> and R<sup>4</sup> are each independently selected from a hydrogen atom, a halogen atom, -NR<sub>f</sub>R<sub>g</sub>, -CONR<sub>f</sub>R<sub>g</sub>, -CH=NOR<sub>e</sub>, a C<sub>1</sub>-C<sub>6</sub> alkoxy group, a C<sub>1</sub>-C<sub>6</sub> alkyl group and -T-(CH<sub>2</sub>)<sub>k</sub>-V, wherein the alkyl group and the alkoxy group may be substituted with one or more substituents selected from a hydroxyl group, a C<sub>1</sub>-C<sub>6</sub> alkoxy group, a halogen atom

and -NRfRg;

wherein

Re is selected from a hydrogen atom and C<sub>1</sub>-C<sub>6</sub> alkyl,

wherein the alkyl group may be substituted with one to

three substituents selected from a hydroxyl group, a

C<sub>1</sub>-C<sub>6</sub> alkoxy group, a halogen atom and -NRhRi,

Rf and Rg are each independently selected from a hydrogen

atom, C<sub>1</sub>-C<sub>6</sub> alkyl group and C<sub>1</sub>-C<sub>6</sub> alkylcarbonyl group,

wherein the alkyl group and the alkylcarbonyl group may

be substituted with one to three substituents selected

from a hydroxyl group, a C<sub>1</sub>-C<sub>6</sub> alkoxy group, a halogen

atom and -NRhRi,

Rh and Ri are each independently selected from a hydrogen

atom and C<sub>1</sub>-C<sub>6</sub> alkyl group, wherein the alkyl group may

be substituted with one to three substituents selected

from a hydroxyl group, a halogen atom and a C<sub>1</sub>-C<sub>6</sub> alkoxy

group, or

Rf and Rg, and Rh and Ri together with a nitrogen atom to

which they are attached may form a 4- to 7-heterocycle,

wherein the heterocycle may be substituted with a C<sub>1</sub>-C<sub>6</sub>

alkyl group,

T is an oxygen atom or a single bond; k is an integer

selected from 0 to 4;

V is a 5- to 6-membered heterocyclyl group which may be

substituted with one or more  $Y^3$ ,  $-NRaRb$ ,  
 $CONRaRb$ ,  $-OC(=O)NRaRb$ ,  $-SO_2NRaRb$ ,  
 $-N(-Ra)C(=O)NRa'Rb'$ ,  $-N(-Ra)C(=O)ORD$ ,  $-C(=O)ORD$ ,  
 $-S(=O)_m-$   
 $Rd$ ,  $-O-Rd$ ,  $-OC(=O)Rc$ ,  $-N(-Ra)C(=O)Rc$ ,  
 $-N(Ra)SO_2Rc$ ,  
 $-C(=NRa)NRa'Rb'$ ,  $-C(=NORa)Rc$  or  $-C(=O)Rc$ ;

$R^6$  and  $R^7$  are each independently selected from a hydrogen atom and a halogen atom;

$Z^1$  and  $Z^2$  are each independently selected from a hydrogen atom, a hydroxyl group and  $-O(CHR^{11})OC(=O)R^{12}$ ;


wherein

$R^{11}$  is a hydrogen atom or a  $C_1$ - $C_6$  alkyl group;

$R^{12}$  is a pyrrolidinyl group, a piperidinyl group, a morpholinyl group, a piperazinyl group, an amino  $C_1$ - $C_6$  alkyl group, a mono- or di( $C_1$ - $C_6$  alkyl)amino  $C_1$ - $C_6$  alkyl group, an amino  $C_1$ - $C_6$  alkylamino group or a mono- or di( $C_1$ - $C_6$  alkyl)-amino  $C_1$ - $C_6$  alkylamino group;

Q is a group of

Formula 2



wherein

~~G<sup>1</sup> is C-Y<sup>2</sup> or N;~~

~~ring A is a benzene ring or a 5 to 6 membered  
unsaturated heterocycle; a nitrogen atom present in the  
heterocycle may be an N oxide; and the ring A may be  
substituted with one to three same or different  
substituents W;~~

~~Y<sup>1</sup> and Y<sup>2</sup> are each~~ is independently selected from a  
hydrogen atom, a halogen atom, a C<sub>1</sub>-C<sub>6</sub> alkyl group, a  
C<sub>2</sub>-C<sub>6</sub> alkenyl group, a C<sub>1</sub>-C<sub>6</sub> alkoxy group, a mono- or  
dihydroxy C<sub>1</sub>-C<sub>6</sub> alkyl group, a C<sub>1</sub>-C<sub>6</sub> alkoxy C<sub>1</sub>-C<sub>6</sub> alkoxy  
group, an amino C<sub>1</sub>-C<sub>6</sub> alkoxy group, a (C<sub>1</sub>-C<sub>6</sub> alkyl)amino  
C<sub>1</sub>-C<sub>6</sub> alkoxy group, a di(C<sub>1</sub>-C<sub>6</sub> alkyl)amino C<sub>1</sub>-C<sub>6</sub> alkoxy  
group, a C<sub>1</sub>-C<sub>6</sub> alkoxy C<sub>1</sub>-C<sub>6</sub> alkyl group, an amino C<sub>1</sub>-C<sub>6</sub>  
alkyl group, a (C<sub>1</sub>-C<sub>6</sub> alkyl)amino C<sub>1</sub>-C<sub>6</sub> alkyl group, a  
di(C<sub>1</sub>-C<sub>6</sub> alkyl)amino C<sub>1</sub>-C<sub>6</sub> alkyl group, an amino group, a  
(C<sub>1</sub>-C<sub>6</sub> alkyl)amino group and a di(C<sub>1</sub>-C<sub>6</sub> alkyl)amino  
group;

Wherein

Q is optionally substituted by at least one substituents  
W, where W is a halogen atom, a nitro group, a cyano  
group, a hydroxyl group, -NRaRb, -N=C(-Rc)NRaRb, -  
CONRaRb, -OC(=O)NRaRb, -SO<sub>2</sub>NRaRb, -N(-Ra)C(=O)NRa'Rb',  
-N(-Ra)C(=O)ORD, -N[C(=O)ORD][C(=O)ORD'], -  
C(=O)ORD, -S(=O)<sub>m</sub>-Rd, -O-Rd, -OC(=O)Rc, -N(-  
Ra)C(=O)Rc, -N[C(=O)Rc][C(=O)Rc'], -N(-Ra)SO<sub>2</sub>Rc, -

$N(SO_2Rc)(SO_2Rc')$ ,  $-C(=NORd)NRa'Rb'$ ,  $-C(=NRa)NRa'Rb'$ ,  $-C(=NORa)Rc$ ,  $-C(=O)Rc$ , a  $C_1-C_6$  alkyl group which may be substituted with one or more  $Y^3$ , a  $C_2-C_7$  alkenyl group which may be substituted with one or more  $Y^3$ , a  $C_2-C_7$  alkynyl group which may be substituted with one or more  $Y^3$ , an aryl group which may be substituted with one or more  $Y^3$  or a heteroaryl group which may be substituted with one or more  $Y^3$ ;

$Ra$ ,  $Ra'$ ,  $Rb$ ,  $Rb'$ ,  $Rc$ ,  $Rc'$ ,  $Rd$  and  $Rd'$  are each independently selected from a hydrogen atom, a  $C_1-C_{10}$  alkyl group, a  $C_3-C_8$  cycloalkyl group, a  $C_2-C_8$  alkenyl group, a  $C_2-C_8$  alkynyl group,  $-[(C_1-C_6 \text{ alkylene})-O]_n-(C_1-C_3 \text{ alkyl})$ , a tetrahydropyranyl group, a tetrahydrofuranyl group, an aryl group, a heteroaryl group, and a nitrogen-containing heterocyclyl group (wherein the nitrogen atom on the heterocyclyl group may be substituted with a  $C_1-C_3$  alkyl group); or  $Ra$  and  $Rb$ ,  $Ra'$  and  $Rb'$ ,  $Ra$  and  $Rd$ ,  $Ra$  and  $Ra'$ ,  $Ra$  and  $Rc$ ,  $Rc$  and  $Rc'$ , and  $Rd$  and  $Ra'$  may form a saturated or unsaturated 5- to 6-membered heterocycle by ring-closing at the bonding position of each of these two groups and the heterocycle may be substituted with a  $C_1-C_6$  alkyl group;

Ra, Ra', Rb, Rb', Rc, Rc', Rd and Rd' each may be substituted with one to three same or different substituents selected from Y<sup>3</sup>;

m is an integer selected from 0 to 2;

n is an integer selected from 1 to 4;

Y<sup>3</sup> is a halogen atom, -NRxRy, -C(=O)ORz, -C(=O)Rz, -ORz, -C(=O)NRxRy, -OC(=O)NRxRy, -SO<sub>2</sub>NRxRy, -N(-Rx)C(=O)NRx'Ry', -N(-Rx)C(=O)ORz, -S-Rz, -SO-Rz, -SO<sub>2</sub>-Rz, -OC(=O)Rz, -N(Rx)C(=O)Rz, -C(=NORz)NRx'Ry', -C(=NRx)NRx'Ry', -C(=NORx)Rz, -[O-(C<sub>1</sub>-C<sub>6</sub> alkylene)]<sub>n</sub>-O(C<sub>1</sub>-C<sub>3</sub> alkyl), -N(-Rx)-(C<sub>1</sub>-C<sub>6</sub> alkylene)-O(C<sub>1</sub>-C<sub>3</sub> alkyl), -C(=O)Rz, a C<sub>1</sub>-C<sub>6</sub> alkyl group, a C<sub>2</sub>-C<sub>8</sub> alkenyl group, a C<sub>2</sub>-C<sub>8</sub> alkynyl group, an aryl group or a heteroaryl group;

Rx, Rx', Ry, Ry' and Rz are each independently selected from a hydrogen atom and a C<sub>1</sub>-C<sub>4</sub> alkyl group;

Rx and Ry, Rx and Rx', Rx and Rz, and Rz and Rx' may form a saturated or unsaturated 5-to 6-membered heterocycle by ring-closing at the bonding position of each of these two groups;


a pharmaceutically acceptable salt thereof or a prodrug thereof.



















2. (Original) The compound of claim 1, a pharmaceutically acceptable salt thereof or a prodrug thereof,

wherein R<sup>2</sup> is selected from a halogen atom, a trifluoromethyl group and a trifluoromethoxy group.

3. (Currently Amended) The compound of claim ~~1~~ 2,  
a pharmaceutically acceptable salt thereof or a prodrug  
thereof, wherein Q is a group of the formula selected from

Formula 3







which may be substituted with one to three same or different substituents W.

Claims 4-5 (Cancelled)

6. (Previously Presented) The compound of claim 1, a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein

$R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$  and  $R^5$  are each independently selected from a hydrogen atom, a chlorine atom, a fluorine atom, a bromine atom and a trifluoromethyl group;

$R^6$  and  $R^7$  are hydrogen atoms; and

$Z^1$  and  $Z^2$  are each independently selected from a hydrogen atom, and a hydroxyl group.

7. (Previously Presented) The compound of claim 1, a pharmaceutically acceptable salt thereof or a prodrug thereof,

wherein

$R^3$  and  $R^4$  are each independently selected from a hydrogen atom, a halogen atom, a  $C_1$ - $C_6$  alkyl group which may be substituted with one or more hydroxyl groups or halogen

atoms, a C<sub>1</sub>-C<sub>6</sub> alkoxy group which may be substituted with one or more halogen atoms, and -T-(CH<sub>2</sub>)<sub>k</sub>-V;

T is an oxygen atom or a single bond; k is an integer selected from 0 to 4;

V is a 5- to 6-membered heterocyclyl group which may be substituted with one or more substituents selected from a hydroxy group, an amino group, C<sub>1</sub>-C<sub>6</sub> alkyl group, C<sub>1</sub>-C<sub>6</sub> alkoxy group and C<sub>1</sub>-C<sub>6</sub> alkylcarbonyl group.

8. (Previously Presented) A compound, a pharmaceutically acceptable salt thereof or a prodrug thereof of claim 1 which has Raf inhibiting effect and angiogenesis inhibiting effect and is used for treating cancer, psoriasis, atherosclerosis, chronic rheumatoid arthritis and diabetes.

9. (Previously Presented) A pharmaceutical composition comprising a compound, a pharmaceutically acceptable salt thereof or a prodrug thereof of claim 1 as an active ingredient.

10. (Previously Presented) An Raf inhibitor or an angiogenesis inhibitor comprising a compound, a pharmaceutically acceptable salt thereof or a prodrug thereof of claim 1 as an active ingredient.

11. (Previously Presented) A preventive or

therapeutic agent for a disease selected from cancer,  
psoriasis, atherosclerosis, chronic rheumatoid arthritis and  
diabetes which comprises a compound, a pharmaceutically  
acceptable salt thereof or a prodrug thereof of claim 1 as an  
active ingredient.

Claims 12-13 (Cancelled)